Chemical Structure
(Chemical structure of Rosiglitazone Maleate (SIH-379), a Insulin sensitizing agent. CAS #: 122320-73-4. Molecular Formula: C18H19N3O3S. Molecular Weight: 357.4 g/mol.)
Rosiglitazone Small Molecule
Rosiglitazone Maleate
Purity
>98%
Synonyms
Rosiglitazone; Rosiglitazone Maleate; Insulin sensitizer; 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2; 4-thiazolidinedione; Rosiglitazone small molecule
Host
Synthetic
Purity/Purification
>98%
Form/Format
White to off-white solid
Solubility
Soluble in DMSO (3 mg/ml) or DMF (10 mg/ml)
CAS Number
155141-29-0
Molecular Formula
C18H19N3O3S-C4H4O4
SMILES
C2=C(CC1SC(=O)NC1=O)C=CC(=C2)OCCN(C3=CC=CC=N3)C.O=C(O)\C=C/C(=O)O
InChI
1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
InChI Key
YASAKCUCGLMORW-UHFFFAOYSA-N
PubChem CID
77999
Preparation and Storage
Store at -20 degree C.
Chemical Structure
(Chemical structure of Rosiglitazone Maleate (SIH-379), a Insulin sensitizing agent. CAS #: 122320-73-4. Molecular Formula: C18H19N3O3S. Molecular Weight: 357.4 g/mol.)
Chemical Structure
(Chemical structure of Rosiglitazone Maleate (SIH-379), a Insulin sensitizing agent. CAS #: 122320-73-4. Molecular Formula: C18H19N3O3S. Molecular Weight: 357.4 g/mol.)
Related Product Information for Rosiglitazone small molecule
Rosiglitazone is a potent agonist for PPARgamma with an EC50 of 43 nM for the human receptor. It is anti-diabetic, working as an insulin sensitizer by binding to the PPARgamma receptors in fat cells and making the cells more responsive to insulin.
Product Categories/Family for Rosiglitazone small molecule
References
1. Werner A.L., & Travaglini M.T. (2001) Pharmacotherapy. 21(9): 1082-99. 2. McMorran M., and Vu D. (2001) CMAJ. 165(1): 82-3, 86-7. 3. Malinowski J.M. & Bolesta S. (2000) Clin. Ther. 22(10): 1151-68. 4. Cheng-Lai A., & Levine A. (2000) Heart Dis. 2(4): 326-33. 5. Knock G.A., et al. (1999) Eur. J. Pharmacol. 368(1): 103-9. 6. Balfour J.A., & Plosker G.L. (1999) Drugs. 57(6): 921-30. 7. Parks D.J., et al. (1998) Bioorg. Med. Chem. Lett. 8(24): 3657-8.
Similar Products
Product Notes
The Rosiglitazone (Catalog #AAA808083) is a Small Molecule produced from Synthetic and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "Rosiglitazone, Small Molecule" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
